Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambiotech Bio-Pulsed Exosome for premature ovarian failure
- Development stage
- Preclinical
- Lead developer
- Ascension Medical Biotechnology
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Direct Ovarian
01
Overview
Ambiotech's Bio-Pulsed Exosome therapy for premature ovarian failure (POF) is an extracellular vesicle (EV)-based regenerative treatment currently in preclinical development. Developed by Ambiotech (Ascension Medical Biotechnology), the therapy utilizes proprietary Bio-Pulsed technology to activate stem cells, inducing the production of exosomes with gene profiles specifically modified for therapeutic efficacy in ovarian tissue. The treatment is designed to restore ovarian function through regenerative signaling, aiming to repair damaged tissue and improve cellular health in patients suffering from POF. While the specific molecular targets have not been disclosed, the platform focuses on leveraging the natural signaling capabilities of exosomes to provide a cell-free alternative to traditional stem cell therapies.
- Other names
- Bio-Pulsed Exosome for Premature Ovarian FailureAmbiotech POF exosome therapyAmbiotech extracellular vesicle-based therapy for premature ovarian failure
Beyond the preview
Go deeper on Ambiotech Bio-Pulsed Exosome for premature ovarian failure.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambiotech Bio-Pulsed Exosome for premature ovarian failure.